Genetic architecture of neurodegenerative dementias

Jordi Clarimon; Sonia Moreno-Grau; Laura Cervera-Carles; Oriol Dols-Icardo; Pascual Sánchez-Juan; Agustín Ruiz

doi:10.1016/j.neuropharm.2020.108014

Genetic architecture of neurodegenerative dementias

Jordi Clarimon, Sonia Moreno-Grau, Laura Cervera-Carles, Oriol Dols-Icardo, Pascual Sánchez-Juan, Agustín Ruiz

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Molecular genetics has been an invaluable tool to help understand the molecular basis of neurodegenerative dementias. In this review, we provide an overview of the genetic architecture underlying some of the most prevalent causes of dementia, including Alzheimer's dementia, frontotemporal lobar degeneration, Lewy body dementia, and prion diseases. We also discuss the complexity of the human genome and how the novel technologies have revolutionized and accelerated the way we screen the variety of our DNA. Finally, we also provide some examples about how this genetic knowledge is being transferred into the clinic through personalized medicine.

Original language	English (US)
Article number	108014
Journal	Neuropharmacology
Volume	168
DOIs	https://doi.org/10.1016/j.neuropharm.2020.108014
State	Published - May 15 2020
Externally published	Yes

Keywords

Alzheimer's disease
Frontotemporal dementia
Genetics
Lewy body
Prion
Review

ASJC Scopus subject areas

Pharmacology
Cellular and Molecular Neuroscience

Access to Document

10.1016/j.neuropharm.2020.108014

Cite this

@article{c7110aaf369f4206964a578332f94f6b,

title = "Genetic architecture of neurodegenerative dementias",

abstract = "Molecular genetics has been an invaluable tool to help understand the molecular basis of neurodegenerative dementias. In this review, we provide an overview of the genetic architecture underlying some of the most prevalent causes of dementia, including Alzheimer's dementia, frontotemporal lobar degeneration, Lewy body dementia, and prion diseases. We also discuss the complexity of the human genome and how the novel technologies have revolutionized and accelerated the way we screen the variety of our DNA. Finally, we also provide some examples about how this genetic knowledge is being transferred into the clinic through personalized medicine.",

keywords = "Alzheimer's disease, Frontotemporal dementia, Genetics, Lewy body, Prion, Review",

author = "Jordi Clarimon and Sonia Moreno-Grau and Laura Cervera-Carles and Oriol Dols-Icardo and Pascual S{\'a}nchez-Juan and Agust{\'i}n Ruiz",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Ltd",

year = "2020",

month = may,

day = "15",

doi = "10.1016/j.neuropharm.2020.108014",

language = "English (US)",

volume = "168",

journal = "Neuropharmacology",

issn = "0028-3908",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Genetic architecture of neurodegenerative dementias

AU - Clarimon, Jordi

AU - Moreno-Grau, Sonia

AU - Cervera-Carles, Laura

AU - Dols-Icardo, Oriol

AU - Sánchez-Juan, Pascual

AU - Ruiz, Agustín

PY - 2020/5/15

Y1 - 2020/5/15

N2 - Molecular genetics has been an invaluable tool to help understand the molecular basis of neurodegenerative dementias. In this review, we provide an overview of the genetic architecture underlying some of the most prevalent causes of dementia, including Alzheimer's dementia, frontotemporal lobar degeneration, Lewy body dementia, and prion diseases. We also discuss the complexity of the human genome and how the novel technologies have revolutionized and accelerated the way we screen the variety of our DNA. Finally, we also provide some examples about how this genetic knowledge is being transferred into the clinic through personalized medicine.

AB - Molecular genetics has been an invaluable tool to help understand the molecular basis of neurodegenerative dementias. In this review, we provide an overview of the genetic architecture underlying some of the most prevalent causes of dementia, including Alzheimer's dementia, frontotemporal lobar degeneration, Lewy body dementia, and prion diseases. We also discuss the complexity of the human genome and how the novel technologies have revolutionized and accelerated the way we screen the variety of our DNA. Finally, we also provide some examples about how this genetic knowledge is being transferred into the clinic through personalized medicine.

KW - Alzheimer's disease

KW - Frontotemporal dementia

KW - Genetics

KW - Lewy body

KW - Prion

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=85079617566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079617566&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2020.108014

DO - 10.1016/j.neuropharm.2020.108014

M3 - Review article

C2 - 32097768

AN - SCOPUS:85079617566

SN - 0028-3908

VL - 168

JO - Neuropharmacology

JF - Neuropharmacology

M1 - 108014

ER -

Genetic architecture of neurodegenerative dementias

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this